Xeris Biopharma Holdings, Inc. (LON:0A8E)
6.80
-0.18 (-2.51%)
Feb 12, 2026, 3:59 PM GMT
Xeris Biopharma Holdings Employees
Xeris Biopharma Holdings had 394 employees as of December 31, 2024. The number of employees increased by 17 or 4.51% compared to the previous year.
Employees
394
Change (1Y)
17
Growth (1Y)
4.51%
Revenue / Employee
502.51K GBP
Profits / Employee
-29.53K GBP
Market Cap
840.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 394 | 17 | 4.51% |
| Dec 31, 2023 | 377 | 22 | 6.20% |
| Dec 31, 2022 | 355 | 61 | 20.75% |
| Dec 31, 2021 | 294 | 114 | 63.33% |
| Sep 30, 2021 | 325 | 153 | 88.95% |
| Jun 30, 2021 | 253 | 65 | 34.57% |
| Mar 31, 2021 | 209 | 10 | 5.03% |
| Dec 31, 2020 | 180 | -22 | -10.89% |
| Sep 30, 2020 | 172 | 38 | 28.36% |
| Jun 30, 2020 | 188 | 62 | 49.21% |
| Mar 31, 2020 | 199 | 109 | 121.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genus | 3,190 |
| Oxford Nanopore Technologies | 1,325 |
| Oxford Biomedica | 900 |
| Avacta Group | 151 |
| 4basebio | 110 |
| Scancell Holdings | 60 |
| PureTech Health | 56 |
| SkinBioTherapeutics | 41 |
Xeris Biopharma Holdings News
- 9 days ago - Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity - Seeking Alpha
- 4 weeks ago - XERS: HC Wainwright & Co. Reiterates Buy Rating with $10.00 Price Target | XERS Stock News - GuruFocus
- 5 weeks ago - Xeris Biopharma (XERS) Exceeds 2025 Revenue Expectations - GuruFocus
- 5 weeks ago - Xeris Biopharma expects full-year 2025 revenue above estimates - Seeking Alpha
- 5 weeks ago - Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - Business Wire
- 5 weeks ago - Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday - The Motley Fool
- 7 weeks ago - Director John Johnson Sells 135,400 Shares of Xeris Biopharma Holdings Inc - GuruFocus